News & Updates
Filter by Specialty:

Why not metformin for long COVID in non-diabetics?
03 Dec 2024
byElvira Manzano
Metformin prescribed within a week of SARS-CoV-2 infection was associated with a 53-percent reduction in long COVID or death over 6 months in patients without diabetes or prediabetes, as shown in a simulation study presented at IDWeek 2024.
Why not metformin for long COVID in non-diabetics?
03 Dec 2024
ADA 2022 guidelines improve prescribing rates of SGLT2 inhibitors in T2D patients
02 Dec 2024
The overall utilization rates of SGLT2 inhibitors have increased among patients with type 2 diabetes (T2D) following the release of the 2022 American Diabetes Association (ADA) guidelines.
ADA 2022 guidelines improve prescribing rates of SGLT2 inhibitors in T2D patients
02 Dec 2024
Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
01 Dec 2024
A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).